Ethics and technology hold the key to the success of synthetic biology
Targeted cancer treatments, toxicity sensors and living factories: synthetic biology has the potential to revolutionize science and medicine. But before the technology is ready for real-world applications, more attention needs to be paid to its safety and stability, say experts in a review article published in Current Opinion in Chemical Biology.
Synthetic biology involves engineering microbes like bacteria to program them to behave in certain ways. For example, bacteria can be engineered to glow when they detect certain molecules, and can be turned into tiny factories to produce chemicals.
Synthetic biology has now reached a stage where it’s ready to move out of the lab and into the real world, to be used in patients and in the field. According to Professor Pamela Silver, one of the authors of the article from Harvard Medical School in the US, this move means researchers should increase focus on the safety of engineered microbes in biological systems like the human body.
“Historically, molecular biologists engineered microbes as industrial organisms to produce different molecules,” said Professor Silver. “The more we discovered about microbes, the easier it was to program them. We’ve now reached a very exciting phase in synthetic biology where we’re ready to apply what we’ve developed in the real world, and this is where safety is vital.”
Microbes have an impact on health; the way they interact with animals is being ever more revealed by microbiome research – studies on all the microbes that live in the body – and this is making them easier and faster to engineer. Scientists are now able to synthesize whole genomes, making it technically possible to build a microbe from scratch.
“Ultimately, this is the future – this will be the way we program microbes and other cell types,” said Dr. Silver. “Microbes have small genomes, so they’re not too complex to build from scratch. That gives us huge opportunities to design them to do specific jobs, and we can also program in safety mechanisms.”
One of the big safety issues associated with engineering microbial genomes is the transfer of their genes to wild microbes. Microbes are able to transfer segments of their DNA during reproduction, which leads to genetic evolution. One key challenge associated with synthetic biology is preventing this transfer between the engineered genome and wild microbial genomes.
There are already several levels of safety infrastructure in place to ensure no unethical research is done, and the kinds of organisms that are allowed in laboratories. The focus now, according to Dr. Silver, is on technology to ensure safety. When scientists build synthetic microbes, they can program in mechanisms called kill switches that cause the microbes to self-destruct if their environment changes in certain ways.
Microbial sensors and drug delivery systems can be shown to work in the lab, but researchers are not yet sure how they will function in a human body or a large-scale bioreactor. Engineered organisms have huge potential, but they will only be useful if proven to be reliable, predictable, and cost effective. Today, engineered bacteria are already in clinical trials for cancer, and this is just the beginning, says Dr. Silver.
“The rate at which this field is moving forward is incredible. I don’t know what happened – maybe it’s the media coverage, maybe the charisma – but we’re on the verge of something very exciting. Once we’ve figured out how to make genomes more quickly and easily, synthetic biology will change the way we work as researchers, and even the way we treat diseases.”
Read more: Synthetic biology needs robust safety mechanisms before real world application
The Latest on: Synthetic biology
[google_news title=”” keyword=”Synthetic biology” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Synthetic biology
- Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)on May 2, 2024 at 5:00 am
Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has allowed patent application 17/232,393, titled “Halogenated Xanthene Composition ...
- Programmable Living Materials Created Using Synthetic Biology and 3D Printingon May 2, 2024 at 2:07 am
Scientists are harnessing cells to make new materials that can grow, repair themselves and even respond to their environment.
- Shiru harnesses AI to launch protein discovery platform: ‘It’s like Amazon for proteins…’on May 1, 2024 at 8:17 am
Shiru is launching a first-of-its-kind discovery platform and marketplace for proteins, enabling companies to identify and test proteins.
- Marriage of synthetic biology and 3D printing produces programmable living materialson May 1, 2024 at 6:42 am
Scientists are harnessing cells to make new types of materials that can grow, repair themselves and even respond to their environment. These solid "engineered living materials" are made by embedding ...
- Engineered living materials: Scientists 3D print with bio-ink made from tobacco cellson May 1, 2024 at 5:03 am
Also known as EPLMs, “engineered plant living materials” are a new frontier that marries synthetic biology and 3D printing, an invention that’s inspired many improvements to the mechanism itself as ...
- Crafting Programmable Living Materials With Synthetic Biology & 3D Printingon May 1, 2024 at 4:59 am
New study uses 3D printing and genetically modified plant cells to create complex, self-repairing materials that could revolutionize biomanufacturing and construction. Scientists are harnessing cells ...
- Vaccine Developers Leverage mRNA and Other Powerful Technologieson April 30, 2024 at 5:00 pm
Grint is entrepreneur in residence at the University of California, San Diego, and holds board-level positions in several companies, including Codagenix, which combines live, attenuated virus design ...
- BioP2P’s Matt Gardner to Speak at SynBioBeta Global Synthetic Biology Conferenceon April 30, 2024 at 9:03 am
Matt Gardner, Board President of the California Biomanufacturing Center and Chair of the BioProcess to Product Network (BioP2P), is scheduled to speak at the 2024 SynBioBeta Global Biology Conference.
- Ansa Biotechnologies to Showcase Early Access Customer Success at Upcoming Global Synthetic Biology Conferenceon April 30, 2024 at 5:03 am
Ansa Biotechnologies, Inc., the trusted partner for complex DNA synthesis, today announced its speaker lineup for presentations at the upcoming Global Synthetic Biology (SynBioBeta) Conference in San ...
- Synthetic droplets cause a stir in the primordial soup: Chemotaxis research answers questions about biological movementon April 25, 2024 at 7:14 am
Simple yet profound questions like these are at the heart of curiosity-driven basic research, which focuses on the fundamental principles of natural phenomena. An important example is the process by ...
via Bing News